NUVB - Nuvation Bio Inc. Stock Price, Fair Value and News

$8.38+0.91 (+12.18%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NUVB Price Action

Last 7 days

4.6%

Last 30 days

62.1%

Last 90 days

145.0%

Trailing 12 Months

190.0%

NUVB RSI Chart

NUVB Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-13.21

Price/Sales (Trailing)

62.61

EV/EBITDA

-2.74

Price/Free Cashflow

-15.12

NUVB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NUVB Fundamentals

NUVB Revenue

Revenue (TTM)

45.9M

Rev. Growth (Yr)

-18.11%

Rev. Growth (Qtr)

174.48%

NUVB Earnings

Earnings (TTM)

-217.5M

Earnings Growth (Yr)

-35.38%

Earnings Growth (Qtr)

5.45%

NUVB Profitability

Operating Margin

100.00%

EBT Margin

-473.98%

Return on Equity

-66.74%

Return on Assets

-36.15%

Free Cashflow Yield

-6.61%

NUVB Investor Care

Shares Dilution (1Y)

1.86%

Diluted EPS (TTM)

-0.49

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	33.3M	39.6M	45.9M	0
2024	26.8M	27.8M	27.4M	27.1M
2023	11.5M	16.7M	21.1M	24.6M
2022	3.5M	3.5M	4.8M	7.4M
2021	1.9M	2.1M	2.5M	3.0M
2020	1.5M	1.6M	1.8M	1.9M
2019	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

CEO	Dr. David T. Hung M.D.
WEBSITE	nuvationbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	54

Nuvation Bio Inc. Frequently Asked Questions

What is the ticker symbol for Nuvation Bio Inc.? What does NUVB stand for in stocks?

NUVB is the stock ticker symbol of Nuvation Bio Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuvation Bio Inc. (NUVB)?

As of Wed Dec 03 2025, market cap of Nuvation Bio Inc. is 2.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NUVB stock?

You can check NUVB's fair value in chart for subscribers.

Is Nuvation Bio Inc. a good stock to buy?

The fair value guage provides a quick view whether NUVB is over valued or under valued. Whether Nuvation Bio Inc. is cheap or expensive depends on the assumptions which impact Nuvation Bio Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NUVB.

What is Nuvation Bio Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, NUVB's PE ratio (Price to Earnings) is -13.21 and Price to Sales (PS) ratio is 62.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUVB PE ratio will change depending on the future growth rate expectations of investors.